X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q2 2023 Results Conference Call August 10, 2023 8:30 AM ET

Company Participants

Dan Ferry - LifeSci Advisors

Paula Ragan - CEO

Adam Mostafa - CFO

Murray Stewart - Interim CMO

Mark Baldry - CCO

Conference Call Participants

Stephen Willey - Stifel

Kristen Kluska - Cantor Fitzgerald

Ted Tenthoff - Piper Sandler

Mark Brown - Cowen and Company

Mayank Mamtani - B. Riley

RK - H.C. Wainwright

Trevor Allred - Oppenheimer

Operator

Greetings. Welcome to X4 Pharmaceuticals' Second Quarter 2023 Financial and Operating Results Conference Call. [Operator Instructions] As a reminder, the conference call is being recorded.

It is now my pleasure to introduce your host, Dan Ferry from LifeSci Advisors. Please begin.

Dan Ferry

Thank you, operator. And good morning, everyone. Presenting on today's call will be X4's Chief Executive Officer, Dr. Paula Ragan; and Company's Chief Financial Officer,

Adam Mostafa; and Interim Chief Medical Officer, Dr. Murray Stewart. Following the prepared remarks by each, we will open the call for questions and will be joined by will be joined by Chief Scientific Officer, Art Taveras; and Chief Commercial Officer, Mark Baldry.

As a reminder, on today's call, the company will be making forward-looking statements regarding regulatory and product development plans as well as research activities. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. Description of these risks can be found in X4's filings with the SEC, including this quarter's Form 10-Q, which is expected to be filed after market close today.

I'd now like to turn the call over X4's President and CEO, Dr. Paula Ragan. Paula?

Paula Ragan

Thanks, Dan. Hello everyone. We will be covering a lot of exciting updates this morning. So thank you for joining us on this call. Adam and I will be providing an update on our second quarter and recent events and will then focus the rest of the call on three key updates regarding our ongoing chronic neutropenia program. First, we'll provide some further insights on what we estimate to be the minimum addressable US market for Mavorixafor in the CN populations we are pursuing. Next, we will report on some exciting emerging data from our ongoing Phase II trial. And finally, we will also provide a regulatory update as we prepare for a Phase III clinical trial in 2024. We will then conclude and open it up to your questions.